Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Four-week treatment of linvencorvir (RO7049389) was generally safe and well tolerated, and showed anti-viral activity in chronic hepatitis B (CHB) patients. This study evaluated the efficacy, safety, and pharmacokinetics of 48-week treatment with linvencorvir plus standard of care (SoC) in CHB patients. Methods: This was a multicentre, non-randomized, non-controlled, open-label phase 2 study enrolling three cohorts: nucleos(t)ide analogue (NUC)-suppressed patients received linvencorvir plus NUC (Cohort A, n=32); treatment-naïve patients received linvencorvir plus NUC without (Cohort B, n=10) or with (Cohort C, n=30) pegylated interferon-α (Peg-IFN-α). Treatment duration was 48 weeks, followed by NUC alone for 24 weeks. Results: 68 patients completed the study. No patient achieved functional cure (sustained HBsAg loss and unquantifiable HBV DNA). By Week 48, 89% of treatment-naïve patients (10/10 Cohort B; 24/28 Cohort C) reached unquantifiable HBV DNA. Unquantifiable HBV RNA was achieved in 92% of patients with quantifiable baseline HBV RNA (14/15 Cohort A, 8/8 Cohort B, 22/25 Cohort C) at Week 48 along with partially sustained HBV RNA responses in treatment-naïve patients during follow-up period. Pronounced reductions in HBeAg and HBcrAg were observed in treatment-naïve patients, while HBsAg decline was only observed in Cohort C. Most adverse events were grade 1–2, and no linvencorvir-related serious adverse events were reported. Conclusions: 48-week linvencorvir plus SoC was generally safe and well tolerated, and resulted in potent HBV DNA and RNA suppression. However, 48-week linvencorvir plus NUC with or without Peg-IFN did not result in the achievement of functional cure in any patient.
Abstract
Background/Aims: Four-week treatment of linvencorvir (RO7049389) was generally safe and well tolerated, and showed anti-viral activity in chronic hepatitis B (CHB) patients. This study evaluated the efficacy, safety, and pharmacokinetics of 48-week treatment with linvencorvir plus standard of care (SoC) in CHB patients. Methods: This was a multicentre, non-randomized, non-controlled, open-label phase 2 study enrolling three cohorts: nucleos(t)ide analogue (NUC)-suppressed patients received linvencorvir plus NUC (Cohort A, n=32); treatment-naïve patients received linvencorvir plus NUC without (Cohort B, n=10) or with (Cohort C, n=30) pegylated interferon-α (Peg-IFN-α). Treatment duration was 48 weeks, followed by NUC alone for 24 weeks. Results: 68 patients completed the study. No patient achieved functional cure (sustained HBsAg loss and unquantifiable HBV DNA). By Week 48, 89% of treatment-naïve patients (10/10 Cohort B; 24/28 Cohort C) reached unquantifiable HBV DNA. Unquantifiable HBV RNA was achieved in 92% of patients with quantifiable baseline HBV RNA (14/15 Cohort A, 8/8 Cohort B, 22/25 Cohort C) at Week 48 along with partially sustained HBV RNA responses in treatment-naïve patients during follow-up period. Pronounced reductions in HBeAg and HBcrAg were observed in treatment-naïve patients, while HBsAg decline was only observed in Cohort C. Most adverse events were grade 1–2, and no linvencorvir-related serious adverse events were reported. Conclusions: 48-week linvencorvir plus SoC was generally safe and well tolerated, and resulted in potent HBV DNA and RNA suppression. However, 48-week linvencorvir plus NUC with or without Peg-IFN did not result in the achievement of functional cure in any patient.
참고문헌 (34)
- GBD 2019 Hepatitis B Collaborators, "Global, regional, and national burden of hepatitis B, 1990-2019 : a systematic analysis for the Global Burden of Disease Study 2019", Lancet Gastroenterol Hepatol, 7, pp.796~829 (2022)
- "Hepatitis B. WHO Fact sheets"[URL]
- Lok AS, "Hepatitis B cure : From discovery to regulatory approval", J Hepatol, 67, pp.847~861 (2017)
- Anderson RT, "Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection : Systematic review and metaanalysis", Clin Gastroenterol Hepatol, 19, pp.463~472 (2021)
- European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Song A, "Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma : A meta-analysis", J Viral Hepat, 28, pp.601~612 (2021)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- Lok AS, "Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B", Gastroenterology, 143, pp.619~628 (2012)
- Zhang Q, "Low-level viremia in nucleoside analog-treated chronic hepatitis B patients", Chin Med J(Engl), 134, pp.2810~2817 (2021)
- Choi HSJ, "Aiming for functional cure with established and novel therapies for chronic hepatitis B", Hepatol Commun, 6, pp.935~949 (2022)
- Tout I, "Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B", Antiviral Res, 185, pp.104992~ (2021)
- Fung S, "Getting to HBV cure : The promising paths forward", Hepatology, 76, pp.233~250 (2022)
- Taverniti V, "Capsid assembly modulators as antiviral agents against HBV : Molecular mechanisms and clinical perspectives", J Clin Med, 11, pp.1349~ (2022)
- Yuen MF, "Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection", J Hepatol, 77, pp.642~652 (2022)
- Zoulim F, "Nomenclature of HBV core protein-targeting antivirals", Nat Rev Gastroenterol Hepatol, 19, pp.748~750 (2022)
- Sulkowski MS, "Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection", J Hepatol, 77, pp.1265~1275 (2022)
- Janssen HLA, "Randomised phase 2 study(JADE)of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection", Gut, 72, pp.1385~1398 (2023)
- Zhou X, "In vitro and in vivo antiviral characterization of RO7049389, a novel small molecule capsid assembly modulator for the treatment of chronic hepatitis B", J Hepatol, 68, pp.S770~ (2018)
- Feng S, "A five-in-one first-in-human study to assess safety, tolerability, and pharmacokinetics of RO7049389, an inhibitor of hepatitis B virus capsid assembly, after single and multiple ascending doses in healthy participants", Antimicrob Agents Chemother, 64, pp.e01323-20~ (2020)
- Yuen MF, "Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection : a multicentre, randomised, placebo-controlled, phase 1 trial", Lancet Gastroenterol Hepatol, 6, pp.723~732 (2021)
- Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
- "Cobas® HBV RNA (RUO)"[URL]
- Scholtès C, "Performance of the cobas® HBV RNA automated investigational assay for the detection and quantification of circulating HBV RNA in chronic HBV patients", J Clin Virol, 150-151, pp.105150~ (2022)
- Testoni B, "Serum hepatitis B core-related antigen(HBcrAg)correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients", J Hepatol, 70, pp.615~625 (2019)
- Suslov A, "Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity", J Hepatol, 74, pp.794~800 (2021)
- Wu D, "The potential immune regulation benefit of CpAMs beyond HBV suppression", Lancet Gastroenterol Hepatol, 6, pp.680~682 (2021)
- Berke JM, "Capsid assembly modulators have a dual mechanism of action in primary human hepatocytes infected with hepatitis B virus", Antimicrob Agents Chemother, 61, pp.e00560-17~ (2017)
- Guo F, "HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways", PLoS Pathog, 13, pp.e1006658~ (2017)
- Marcellin P, "Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B", Gastroenterology, 150, pp.134~144 (2016)
- Sonneveld MJ, "Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b : relation to response and HBV genotype", Antivir Ther, 17, pp.9~17 (2012)
- Marcellin P, "Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B", Aliment Pharmacol Ther, 44, pp.957~966 (2016)
- Chang ML, "Hepatitis B flares in chronic hepatitis B : pathogenesis, natural course, and management", J Hepatol, 61, pp.1407~1417 (2014)
- Seo HY, "Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-naïve patients with chronic hepatitis B", Clin Mol Hepatol, 23, pp.154~159 (2017)
- Flink HJ, "Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy", Gut, 54, pp.1604~1609 (2005)